On August 22, 2024, Hikma Pharmaceuticals USA Inc. and Hikma Pharmaceuticals, PLC (collectively Hikma), filed a petition for rehearing en banc, asking the US Court of Appeals for the Federal ...

Buprenorphine (as HCl) 0.3mg/mL; for IM or IV inj. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. The principal action of therapeutic ...

This systematic review looked at 26 studies of buprenorphine-precipitated withdrawal, including 5 randomized trials, all conducted between 2002 and 2023 and with a total sample size of 4,497 patients.

Patients who received higher doses of buprenorphine, a common medication used to alleviate opioid withdrawal and cravings, were less likely to be hospitalized and less likely to discontinue ...

Hikma Pharmaceuticals PLC HIK shares rallied 1.12% to £19.00 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the FTSE 100 Index UKX falling 1.36% to ...

Hikma Pharmaceuticals' corporate investment arm Hikma Ventures has launched a $30 million digital health fund in Jordan, focusing on therapeutic and diagnostic start-ups. The company's roots are ...

Hikma Pharmaceuticals PLC HIK shares were unchanged Tuesday at £19.11, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.48% to ...

Hikma Pharmaceuticals Usa Inc was founded in 2011 and operates in Eatontown, United States. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100 ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...